[Cytostatic therapy of metastasizing cancers: therapeutic indications and limitations (author's transl)].
The role of cytostatic drugs in the treatment of patients with advanced, metastasizing tumours and certain-therapeutic regimes are discussed in respect to the following tumours: breast cancer, gynaecological tumours, urinary tract cancers, tumours of the  head and neck, lung cancer and bone and soft tissue sarcomas. Recent progress in the management of these patients is outlined, whilst the limitations of cytotoxic treatment, with the inherent possibility of potentially fatal complications, are emphasized.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy; D001943:Breast Neoplasms / Q000601:surgery; D001984:Bronchial Neoplasms / Q000188:drug therapy; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D008297:Male; D009362:Neoplasm Metastasis / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D011183:Postoperative Complications / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy; D013736:Testicular Neoplasms / Q000188:drug therapy; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents
Zytostatische Therapie metastasierender Karzinome: Möglichkeiten und Grenzen